decemb
sever
acut
respiratori
syndrom
coronaviru
emerg
wuhan
hubei
provinc
china
specif
treatment
establish
coronaviru
far
therefor
urgent
need
identifi
effect
antivir
agent
treatment
diseas
sever
approv
drug
lopinavir
evalu
report
nelfinavir
proteas
inhibitor
potent
inhibit
replic
effect
concentr
inhibit
nelfinavir
respect
lowest
nine
proteas
inhibitor
includ
lopinavir
trough
peak
serum
concentr
nelfinavir
three
six
time
higher
drug
result
suggest
nelfinavir
potenti
candid
drug
treatment
assess
patient
authorfund
right
reserv
reus
allow
without
permiss
decemb
novel
betacoronaviru
design
sever
acut
respiratori
syndrom
coronaviru
emerg
wuhan
hubei
provinc
china
march
confirm
case
death
report
countriesterritoriesarea
affect
specif
treatment
establish
coronaviru
outbreak
sever
acut
respiratori
syndrom
sar
screen
approv
drug
identifi
least
two
human
immunodefici
viru
proteas
inhibitor
lopinavir
nelfinavir
compound
inhibit
sarscov
replic
vitro
openlabel
studi
sar
patient
group
treat
lopinavirritonavir
mg
mg
respect
addit
ribavirin
show
better
clinic
outcom
control
group
treat
ribavirin
rel
similar
sarscov
expect
drug
effect
treatment
patient
select
candid
drug
clinic
evalu
data
antivir
activ
vitro
great
help
howev
basic
inform
effect
concentr
proteas
inhibitor
abrog
replic
thu
present
studi
evalu
antivir
activ
nine
approv
proteas
inhibitor
vitro
evalu
nine
proteas
inhibitor
effect
concentr
ec
cytotox
concentr
cc
select
index
si
cc
ec
analyz
moreov
base
mean
peak
trough
serum
concentr
c
max
c
trough
compound
human
c
max
ec
ratio
c
max
ec
c
trough
ec
ratio
c
trough
ec
calcul
assess
safeti
efficaci
compound
among
inhibitor
test
high
concentr
drug
requir
inhibit
replic
amprenavir
ec
cc
si
darunavir
ec
cc
si
indinavir
ec
cc
si
fig
h
j
tipranavir
inhibit
replic
si
rel
low
ec
cc
si
fig
j
ritonavir
ec
cc
si
saquinavir
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ec
cc
si
atazanavir
ec
cc
si
suppress
less
fig
e
j
lopinavir
clinic
test
patient
sar
block
replic
low
concentr
rang
si
rel
high
among
nine
inhibitor
ec
cc
si
fig
j
notabl
nelfinavir
ec
cc
si
potent
inhibit
viru
replic
lowest
concentr
exhibit
highest
si
test
proteas
inhibitor
fig
j
examin
target
step
proteas
inhibitor
viru
life
cycl
timeofaddit
assay
perform
intracellular
viral
rna
quantifi
hpi
vari
time
drug
addit
nelfinavir
lopinavir
suppress
multipl
viral
rna
cell
even
drug
ad
hpi
fig
result
suggest
drug
function
postentri
step
next
c
max
ec
ratio
c
trough
ec
ratio
nine
compound
calcul
estim
clinic
efficaci
nelfinavir
c
max
ec
c
trough
ec
lopinavir
c
max
ec
c
trough
ec
tipranavir
c
max
ec
c
trough
ec
exhibit
c
trough
ec
ratio
higher
one
fig
ritonavir
exceed
one
c
max
ec
ratio
c
trough
ec
ratio
c
max
ec
c
trough
ec
saquinavir
c
max
ec
c
trough
ec
atazanavir
c
max
ec
c
trough
ec
amprenavir
c
max
ec
c
trough
ec
darunavir
c
max
ec
c
trough
ec
indinavir
c
max
ec
c
trough
ec
could
reach
one
c
max
ec
ratio
result
suggest
nelfinavir
lopinavir
tipranavir
achiev
ec
drug
human
effect
treatment
patient
nelfinavir
show
lowest
ec
highest
si
second
highest
c
max
ec
ratio
highest
c
trough
ec
ratio
among
test
proteas
inhibitor
data
indic
nelfinavir
best
nine
drug
potenti
drug
candid
treatment
lopinavir
show
inferior
result
nelfinavir
name
higher
ec
lower
si
lower
c
max
ec
ratio
lower
c
trough
ec
ratio
nelfinavir
recent
random
control
openlabel
trial
lopinavirritonavir
significantli
acceler
clinic
improv
reduc
mortal
decreas
throat
viral
rna
amount
patient
sever
one
reason
efficaci
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
lopinavirritonavir
confirm
clinic
trial
might
associ
insuffici
c
max
ec
c
trough
ec
ratio
treat
sever
remain
determin
whether
earlier
lopinavirritonavir
treatment
mild
could
clinic
benefit
tipranavir
show
highest
c
max
ec
ratio
second
highest
c
trough
ec
ratio
test
drug
c
max
c
trough
much
higher
test
drug
fig
sinc
si
tipranavir
less
nelfinavir
vs
nelfinavir
seem
better
tipranavir
low
si
tipranavir
may
rais
concern
advers
effect
patient
find
reveal
nelfinavir
highli
effect
inhibit
replic
vitro
high
c
max
ec
c
tough
ec
ratio
suggest
nelfinavir
potenti
candid
drug
treatment
assess
patient
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
fig
antivir
activ
proteas
inhibitor
ai
vero
cell
infect
moi
differ
concentr
indic
proteas
inhibitor
incub
h
viral
yield
cell
supernat
quantifi
qrtpcr
cytotox
drug
vero
cell
measur
mt
assay
left
right
yax
graph
stand
mean
inhibit
viru
yield
mean
cytotox
drug
respect
experi
perform
triplic
j
ec
cc
si
c
max
c
trough
proteas
inhibitor
k
c
max
ec
ratio
c
trough
ec
ratio
proteas
inhibitor
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
